Anaphylaxis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

September 2022 | 57 pages | ID: A154F40A4147EN
Global Markets Direct

Abstracts

Anaphylaxis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anaphylaxis - Drugs In Development, 2022, provides an overview of the Anaphylaxis (Immunology) pipeline landscape.

Anaphylaxis is a severe, potentially life-threatening allergic reaction. Anaphylaxis symptoms include dizziness, nausea, vomiting or diarrhea, feeling of warmth, constriction of the airways and a swollen tongue or throat. Risk factors include personal history of anaphylaxis, allergies or asthma and family history. Treatment includes beta-agonist, antihistamines and cortisone.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anaphylaxis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Anaphylaxis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anaphylaxis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Anaphylaxis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 6, 1, 2, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Anaphylaxis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Anaphylaxis (Immunology).
• The pipeline guide reviews pipeline therapeutics for Anaphylaxis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Anaphylaxis (Immunology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Anaphylaxis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Anaphylaxis (Immunology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Anaphylaxis (Immunology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Anaphylaxis (Immunology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Anaphylaxis - Overview
Anaphylaxis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Anaphylaxis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Anaphylaxis - Companies Involved in Therapeutics Development
Allakos Inc
Aquestive Therapeutics Inc
ARS Pharmaceuticals Inc
BioArdis LLC
Bryn Pharma LLC
Crossject SA
Hoth Therapeutics Inc
Klaria Pharma Holding AB
Nasus Pharma Ltd
Orexo AB
Pharmacin BV
PureIMS BV
Anaphylaxis - Drug Profiles
AK-006 - Drug Profile
Product Description
Mechanism Of Action
AQST-109 - Drug Profile
Product Description
Mechanism Of Action
History of Events
epinephrine - Drug Profile
Product Description
Mechanism Of Action
History of Events
epinephrine - Drug Profile
Product Description
Mechanism Of Action
epinephrine - Drug Profile
Product Description
Mechanism Of Action
History of Events
epinephrine - Drug Profile
Product Description
Mechanism Of Action
History of Events
epinephrine - Drug Profile
Product Description
Mechanism Of Action
History of Events
epinephrine - Drug Profile
Product Description
Mechanism Of Action
History of Events
epinephrine - Drug Profile
Product Description
Mechanism Of Action
HLK-0006 - Drug Profile
Product Description
Mechanism Of Action
HT-KIT - Drug Profile
Product Description
Mechanism Of Action
History of Events
Monoclonal Antibody to Antagonize FcgR1 for Autoimmune Arthritis, Pulmonary Inflammation, Systemic Anaphylaxis and Thrombocytopenia - Drug Profile
Product Description
Mechanism Of Action
Monoclonal Antibody to Antagonize FcgRIIa for Autoimmune Arthritis, Pulmonary Inflammation, Systemic Anaphylaxis and Thrombocytopenia - Drug Profile
Product Description
Mechanism Of Action
MRGPRX2 Antagonist - Drug Profile
Product Description
Mechanism Of Action
OX-640 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Anaphylaxis - Dormant Projects
Anaphylaxis - Product Development Milestones
Featured News & Press Releases
Sep 13, 2022: Bryn Pharma announces completion of its pivotal study comparing UTULY epinephrine intranasal spray vs. 0.3 mg epinephrine autoinjector for the treatment of anaphylaxis
Sep 01, 2022: First patent issued in Europe for Orexo’s adrenaline product OX640
Jul 11, 2022: Aquestive Therapeutics reports positive results from final two arms of EPIPHAST Trial Supporting performance and real-world functionality of AQST-109 Epinephrine Oral Film
Jul 05, 2022: Orexo's nasal adrenaline rescue medication OX640 enters clinical development
Jun 15, 2022: Aquestive Therapeutics reports positive initial topline data from part 3 of EPIPHAST trial evaluating AQST-109 epinephrine oral Film
Apr 12, 2022: Aquestive Therapeutics reports positive topline data from part 2 of EPIPHAST trial evaluating AQST-109 epinephrine oral film
Mar 17, 2022: Aquestive Therapeutics receives FDA Fast Track Designation for AQST-109 for emergency treatment of allergic reactions including anaphylaxis
Feb 28, 2022: ARS Pharmaceuticals to share new data at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting
Feb 28, 2022: Aquestive Therapeutics presented positive topline Phase 1 results for AQST-109 epinephrine oral film at American Academy of Allergy, Asthma, and Immunology (AAAAI) annual meeting
Feb 25, 2022: Aquestive Therapeutics reports positive topline data from part 1 of EPIPHAST Trial evaluating AQST-109 epinephrine oral film
Feb 24, 2022: Aquestive Therapeutics announces FDA Clearance of Investigational New Drug Application (IND) for AQST-109 Epinephrine Oral Film
Feb 01, 2022: Phase 1 trial shows epinephrine can meet therapeutic thresholds when administered sublingually
Dec 13, 2021: Aquestive Therapeutics receives written response to pre-IND submission for AQST-109 (epinephrine prodrug sublingual film) and begins recruitment for its epinephrine film pharmacokinetic and safety trial (EPIPHAST)
Dec 02, 2021: Orexo develops a nasal adrenaline medication based on the novel amorphOX platform
Nov 08, 2021: Hoth Therapeutics Inks API and drug product contracts with WuXi STA to advance manufacturing of HT-KIT cancer therapeutic
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Anaphylaxis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Anaphylaxis - Pipeline by Allakos Inc, 2022
Anaphylaxis - Pipeline by Aquestive Therapeutics Inc, 2022
Anaphylaxis - Pipeline by ARS Pharmaceuticals Inc, 2022
Anaphylaxis - Pipeline by BioArdis LLC, 2022
Anaphylaxis - Pipeline by Bryn Pharma LLC, 2022
Anaphylaxis - Pipeline by Crossject SA, 2022
Anaphylaxis - Pipeline by Hoth Therapeutics Inc, 2022
Anaphylaxis - Pipeline by Klaria Pharma Holding AB, 2022
Anaphylaxis - Pipeline by Nasus Pharma Ltd, 2022
Anaphylaxis - Pipeline by Orexo AB, 2022
Anaphylaxis - Pipeline by Pharmacin BV, 2022
Anaphylaxis - Pipeline by PureIMS BV, 2022
Anaphylaxis - Dormant Projects, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Anaphylaxis, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022